# Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

> **NCT04383210** · PHASE2 · TERMINATED · sponsor: **Elevation Oncology** · enrollment: 54 (actual)

## Conditions studied

- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
- Pancreatic Cancer
- Lung Cancer
- Head and Neck Cancer
- Breast Cancer
- Kidney Cancer
- Colorectal Cancer
- Bladder Cancer
- Ovarian Cancer
- Sarcoma
- Gallbladder Cancer
- Bile Duct Cancer
- Esophageal Cancer
- Uterine Cancer
- Cholangiocarcinoma
- Prostate Cancer

## Interventions

- **DRUG:** Seribantumab

## Key facts

- **NCT ID:** NCT04383210
- **Lead sponsor:** Elevation Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-29
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04383210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04383210, "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04383210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*